A5016579200- Growth Hormone and Insulin-like Growth Factors
- Cancer, Hypoxia, and Metabolism
- Pituitary Gland Disorders and Treatments
- Extracellular vesicles in disease
- MicroRNA in disease regulation
- Diet and metabolism studies
- Birth, Development, and Health
- Adipose Tissue and Metabolism
- Metabolism, Diabetes, and Cancer
- Pancreatic and Hepatic Oncology Research
- Digestive system and related health
- Trypanosoma species research and implications
- Neuroendocrine Tumor Research Advances
- Cancer Cells and Metastasis
- Tuberculosis Research and Epidemiology
- Drug Transport and Resistance Mechanisms
- Circular RNAs in diseases
- PI3K/AKT/mTOR signaling in cancer
- ATP Synthase and ATPases Research
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- FOXO transcription factor regulation
- Cytokine Signaling Pathways and Interactions
- Biochemical and Molecular Research
- Diabetes and associated disorders
Biotechnology Institute
2017-2024
Ohio University
2014-2024
Edison (Italy)
2024
Ohio University Lancaster
2019-2023
AstraZeneca (India)
2014
AstraZeneca (United Kingdom)
2013
Abstract Studies in multiple species indicate that reducing growth hormone (GH) action enhances healthy lifespan. In fact, GH receptor knockout (GHRKO) mice hold the Methuselah prize for world's longest‐lived laboratory mouse. We previously demonstrated GHR ablation starting at puberty (1.5 months), improved insulin sensitivity and female lifespan but results markedly reduced body size. this study, we investigated effects of disruption mature‐adult 6 months old (6mGHRKO). These exhibited...
// Reetobrata Basu 1, 2 , Shiyong Wu John J. Kopchick 2, 3 1 Edison Biotechnology Institute, Ohio University, Athens, Ohio, USA Molecular and Cell Biology Program, University Heritage College of Osteopathic Medicine, Correspondence to: Kopchick, email: kopchick@ohio.edu Keywords: growth hormone (GH), receptor (GHR), melanoma, cancer, IGF-1 Received: November 04, 2016 Accepted: January 24, 2017 Published: February 16, ABSTRACT Recent reports have confirmed highest levels (GH) (GHR)...
Moxifloxacin has shown excellent activity against drug-sensitive as well drug-resistant tuberculosis (TB), thus confirming DNA gyrase a clinically validated target for discovering novel anti-TB agents. We have identified inhibitors in the pyrrolamide class which kill Mycobacterium through inhibition of ATPase catalyzed by GyrB domain gyrase. A homology model M. H37Rv was used deciphering structure-activity relationship and binding interactions with mycobacterial enzyme. Proposed were later...
Pituitary derived and peripherally produced growth hormone (GH) is a crucial mediator of longitudinal growth, organ development, metabolic regulation with tissue specific, sex age-dependent effects. GH its cognate receptor (GHR) are expressed in several forms cancer have been validated as an anti-cancer target through large body vitro, vivo epidemiological analyses. However, the underlying molecular mechanisms action prognosis therapeutic response had sparse until recently. This review...
Chemotherapy treatment against pancreatic ductal adenocarcinoma (PDAC) is thwarted by tumoral activation of multiple therapy-resistance pathways. The growth hormone (GH) – GH receptor (GHR) pair a covert driver multimodal therapy resistance in cancer, and overexpressed PDAC tumors, yet the therapeutic potential targeting same has not been explored. Here, we report that GHR expression negative prognostic factor patients with PDAC. Combinations gemcitabine different antagonists (GHRAs)...
Growth hormone (GH) facilitates therapy resistance in the cancers of breast, colon, endometrium, and melanoma. The GH-stimulated pathways responsible for this were identified as suppression apoptosis, induction epithelial-to-mesenchymal transition (EMT), upregulated drug efflux by increased expression ATP-binding cassette containing multidrug pumps (ABC-transporters). In extremely drug-resistant melanoma, ABC-transporters have also been reported to mediate sequestration intracellular...
Knockdown of GH receptor (GHR) in melanoma cells vitro downregulates ATP-binding cassette-containing (ABC) transporters and sensitizes them to anti-cancer drug treatments. Here we aimed determine whether a GHR antagonist (GHRA) could control cancer growth by sensitizing tumors therapy through downregulation ABC vivo. We intradermally inoculated Fluc-B16-F10 mouse into GHA mice, transgenic for (GHRA), observed marked reduction tumor size, mass tumoral signaling. Moreover, constitutive GHRA...
Chemotherapy treatment against pancreatic ductal adenocarcinoma (PDAC) is thwarted by tumoral activation of multiple therapy resistance pathways. The growth hormone (GH)-GH receptor (GHR) pair a covert driver multimodal in cancer and overexpressed PDAC tumors, yet the therapeutic potential targeting same has not been explored. Here, we report that GHR expression negative prognostic factor patients with PDAC. Combinations gemcitabine different antagonists (GHRAs) markedly improve outcomes...
Growth hormone (GH) and the GH receptor (GHR) are expressed in a wide range of malignant tumors including melanoma. However, effect GH/insulin-like growth factor (IGF) on melanoma vivo has not yet been elucidated. Here we assessed physical molecular effects mouse B16-F10 human SK-MEL-30 cells vitro. We then corroborated these observations with syngeneic two lines different levels GH/IGF: bovine transgenic mice (bGH; high GH, IGF-1) GHR gene-disrupted or knockout (GHRKO; low IGF-1). In vitro,...
Many patients with acromegaly, a hormonal disorder excessive growth hormone (GH) production, report pain in joints. We undertook this study to characterize the joint pathology of mice overexpression bovine GH (bGH) or receptor antagonist (GHa) and investigate effect on regulation chondrocyte cellular metabolism.
Human growth hormone (hGH) is a pituitary-derived endocrine protein that regulates several critical postnatal physiologic processes including growth, organ development, and metabolism. Following adulthood, GH also regulator of multiple pathologies like fibrosis, cancer, diabetes. Therefore, there significant pharmaceutical interest in developing antagonists hGH action. Currently, single FDA-approved antagonist the receptor (hGHR) prescribed for treating patients with acromegaly discovered...
Excess circulating human growth hormone (hGH) in vivo is linked to metabolic and disorders such as cancer, diabetes, acromegaly. Consequently, there considerable interest developing antagonists of hGH action. Here, we present the design, synthesis, characterization a 16-residue peptide (site 1-binding helix [S1H]) that inhibits hGH-mediated STAT5 phosphorylation cultured cells. S1H was designed direct sequence mimetic site 1 mini-helix (residues 36-51) wild-type acts by inhibiting...
Drug resistance in melanoma is a major hindrance cancer therapy. Growth hormone (GH) plays pivotal role contributing to chemotherapy. Knocking down or blocking the GH receptor has been shown sensitize tumor cells Extensive studies have demonstrated that exosomes, subset of extracellular vesicles, play an important drug by transferring key factors In this study, we explore how modulates exosomal cargoes from and their resistance. We treated with GH, doxorubicin, GHR antagonist, pegvisomant,...
Abstract A rare 20K isoform of GH-V (here abbreviated as GHv) was discovered in 1998. To date, only 1 research article has characterized this vivo, observing that GHv treatment male high-fat fed rats had several GH-like activities, but unlike GH lacked diabetogenic and lactogenic activities failed to increase IGF-1 or body length. Therefore, the current study conducted further characterize vivo a separate species GH-deficient model (GH-/- mice) with both sexes represented. GHv-treated GH-/-...
Abstract Bovine growth hormone (bGH) transgenic mice mimic the clinical condition of acromegaly, having high circulating (GH) levels. These are giant, have decreased adipose tissue (AT) mass, impaired glucose metabolism and a shortened lifespan. The detrimental effects excess GH been suggested, in part, to be result its depot‐specific actions on AT. To investigate this relationship, we evaluated gene expression, biological mechanisms, cellular pathways predicted microRNA (miRNA) two AT...
Mycobacterium tuberculosis (Mtb) DNA gyrase ATPase was the target of a drug discovery program. The low specific activity Mtb prompted use smegmatis (Msm) enzyme as surrogate for lead generation, since it had 20-fold higher activity. Addition GyrA or did not significantly increase Msm GyrB ATPase, and an assay developed using alone. Inhibition correlated well with inhibition supercoiling across three chemical scaffolds, justifying its use. As IC50 compounds approached concentration, assays...